![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260922_Roche_Therapeutic_Indications-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Roche<\/p>\n Event Type<\/strong><\/p>\n Clinical Trial Data Readout<\/p>\n Modality<\/strong><\/p>\n Peptide (Biased Dual Agonist)<\/p>\n Asset<\/strong><\/p>\n Enicepatide (CT-388)<\/p>\n Target<\/strong><\/p>\n GLP-1 \/ GIP receptors<\/p>\n Disease Area<\/strong><\/p>\n Type 2 Diabetes<\/p>\n Roche reported that once weekly enicepatide met both primary endpoints in the randomized Phase 2 CT 388 104 study. At 24 mg, mean HbA1c fell 2.65 percentage points and body weight fell 15.5 percent at Week 48. Participants with baseline HbA1c above 8.5 percent had a 4.13 point reduction; 90 percent reached the diabetes target and 62 percent reached normoglycemia.<\/p>\n The study enrolled 447 adults with type 2 diabetes and overweight or obesity and compared several enicepatide doses with placebo. The company reported dose dependent changes, no weight loss plateau at Week 48, low discontinuation of about 2 percent and no new safety signal. Full adverse event, hypoglycemia, gastrointestinal, gallbladder and pancreatic data remain pending.<\/p>\n Enicepatide is a dual GLP 1 and GIP receptor agonist engineered for minimal beta arrestin recruitment, a signaling profile hypothesized to reduce receptor internalization and desensitization. Roche is already running Phase 3 chronic weight management studies and plans a glycemic control program and cardiovascular outcome trials.<\/p>\n Interpretation one is that enicepatide could compete at the high end of incretin efficacy while controlling diabetes. The magnitude and proportion reaching low HbA1c are clinically notable. Against this, cross trial comparisons with tirzepatide and other agents are unreliable because populations, estimands, titration and missing data handling differ.<\/p>\n Interpretation two is that biased receptor signaling produces durable pharmacology. Continued weight loss without plateau is consistent with that hypothesis but does not prove the molecular cause. Human receptor occupancy, comparative dose exposure and long term tolerability are needed. Large cardiovascular studies will determine whether biomarker and weight improvements translate into outcome benefit.<\/p>\n Upgrade evidence includes peer reviewed dose specific data, low discontinuation, reproducible Phase 3 weight and HbA1c effects and cardiovascular safety. A tolerability driven dose ceiling, high treatment discontinuation estimand gap or weak outcomes evidence would reduce differentiation.<\/p>\n Enicepatide was originated by Carmot Therapeutics and acquired by Roche. It activates GLP 1 and GIP receptors to reduce appetite and improve glucose dependent insulin signaling. The obesity and diabetes market already contains effective weekly incretins, so differentiation requires durable efficacy, tolerability, convenient dosing, cardiovascular benefit and scalable peptide manufacturing.<\/p>\n The randomized magnitude makes this a high importance positive signal. Enicepatide appears competitive on both glycemia and weight, and the low reported discontinuation rate is encouraging. Claims of best in disease or signaling driven superiority remain unproven until the complete dataset and Phase 3 replication are available.<\/p>\n Signal Importance: 5 of 5. Signal Direction: positive. Confidence in Facts: high for disclosed randomized topline results. Confidence in Interpretation: moderate because comparisons and mechanistic attribution require full data.<\/p>\n","protected":false},"excerpt":{"rendered":" Roche reported that once weekly enicepatide met both primary endpoints in the randomized Phase 2 CT 388 104 study. At 24 mg, mean HbA1c fell 2.65 percentage points and body weight fell 15.5 percent…<\/p>\n","protected":false},"author":1,"featured_media":3381,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[843,25,109],"class_list":["post-3365","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-enicepatide","tag-roche","tag-type-2-diabetes"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3365"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3365\/revisions"}],"predecessor-version":[{"id":3393,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3365\/revisions\/3393"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3381"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3365"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n